Investigation of Reduced Susceptibility to Glycopeptides among Methicillin-Resistant
            <i>Staphylococcus aureus</i>
            Isolates from Patients in Ireland and Evaluation of Agar Screening Methods for Detection of Heterogeneously Glycopeptide-Intermediate
            <i>S. aureus</i>

Fitzgibbon, Margaret; Rossney, Angela S.; O’Connell, Brian

doi:10.1128/jcm.00836-07

Cited by 36 publications

(37 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various screening methods for strains with reduced vancomycin susceptibilities have been described previously (33,34); however, confirmation of the resistance phenotypes of screening-positive isolates by population analyses is recommended (8,18). This study revealed a slight increase in strains with reduced vancomycin susceptibilities over time at a university hospital in northeast Thailand.…”

Section: ϫ6mentioning

confidence: 83%

The First Vancomycin-Intermediate Staphylococcus aureus Strains Isolated from Patients in Thailand

et al. 2009

View full text Add to dashboard Cite

Section: ϫ6mentioning

confidence: 83%

The First Vancomycin-Intermediate Staphylococcus aureus Strains Isolated from Patients in Thailand

et al. 2009

View full text Add to dashboard Cite

“…After the first reports of VISA and hVISA from Japan, it did not take long for this resistance phenotype to be recognized around the world. Strains of S. aureus (predominately MRSA) demonstrating the hVISA or VISA phenotype have now been reported for many countries including the United States, Japan, Australia, France, Scotland, Brazil, South Korea, Hong Kong, South Africa, Thailand, Israel, and others (22,67,69,77,79,82,94,158,167,194,195,206,258,284,300,326,327,331,352,354,366,373). A retrospective analysis of stored isolates detected previously unrecognized hVISA/VISA strains at least back to 1987 in the United States and back to a similar period in France, Spain, and Germany (11,22,39,276,288); however, there has been some concern about the potential loss of resistance during prolonged storage, which could impact results of such retrospective analyses.…”

Section: Global Epidemiology and Associated Features Of Hvisa And Visamentioning

confidence: 99%

“…The use of BHIA with 3 g vancomycin per ml inoculated with 10 l of a 0.5-McFarland-standard suspension had a high false-positive rate reported by one study (165). Fitzgibbon et al assessed a range of screening media for the detection of hVISA (MHA with 5 g teicoplanin per ml and BHIA with 5 g teicoplanin per ml), all inoculated with 10 l of a 0.5-McFarland-standard suspension, a 2-McFarland-standard suspension, and a BHIB stationary-phase culture (82). The hVISA-positive isolates were confirmed by PAP but included isolates that were positive for hetero-teicoplanin resistance but negative for hVISA by PAP.…”

Section: Hvisamentioning

confidence: 99%

Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

et al. 2010

View full text Add to dashboard Cite

SUMMARY The emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past decade has provided a challenge to diagnostic microbiologists to detect these strains, clinicians treating patients with infections due to these strains, and researchers attempting to understand the resistance mechanisms. Recent data show that these strains have been detected globally and in many cases are associated with glycopeptide treatment failure; however, more rigorous clinical studies are required to clearly define the contribution of hVISA to glycopeptide treatment outcomes. It is now becoming clear that sequential point mutations in key global regulatory genes contribute to the hVISA and VISA phenotypes, which are associated predominately with cell wall thickening and restricted vancomycin access to its site of activity in the division septum; however, the phenotypic features of these strains can vary because the mutations leading to resistance can vary. Interestingly, changes in the staphylococcal surface and expression of agr are likely to impact host-pathogen interactions in hVISA and VISA infections. Given the subtleties of vancomycin susceptibility testing against S. aureus, it is imperative that diagnostic laboratories use well-standardized methods and have a framework for detecting reduced vancomycin susceptibility in S. aureus.

show abstract

“…Agar screening test was performed as described previously (Fitzgibbon et al, 2007). All isolates were screened on brain heart infusion (BHI) agar supplemented with 4 g/ml vancomycin (BHIV4) and 6 g/ml vancomycin (BHIV6) by using 10 l of bacterial suspensions of a 0.5 McFarland suspension.…”

Section: Vancomycin Agar Screening Testmentioning

confidence: 99%

“…hVISA was screened by MET described by (Fitzgibbon et al, 2007). Namely, 200 l of 2.0 MaFarland suspensions was pipetted onto a BHI agar plate.…”

Section: The Macro E Test (Met)mentioning

confidence: 99%

Molecular characteristic of Staphylococcus aureus isolates in a Chinese teaching hospital

Ma¹,

Chen²,

Zhou³

et al. 2011

Afr. J. Microbiol. Res.

View full text Add to dashboard Cite

The aim of this study is to investigate the genetic backgrounds of methicillin susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) isolates isolated from clinical specimens of the patients with verified infections in a Chinese teaching hospital. Macro E test (MET) was used to detect hVISA and multilocus sequence typing (MLST) was used to determine the STs of the selected isolates. The genotypes of SCCmec were determined by multiplex polymerase chain reaction (PCR) in MRSA isolates. Panton-valentine leucocidin (PVL) genes were also detected by PCR. Among 273 S. aureus isolates, hospital-acquired methicillin-resistant Staphylococcus aureus (HA-MRSA), community-associated methicillin-resistant S. aureus (CA-MRSA), hospital-acquired methicillin susceptible Staphylococcus aureus (HA-MSSA) and community-associated methicillin susceptible Staphylococcus aureus (CA-MSSA) isolates accounted for 55.6, 1.5, 36.3, and 6.6%, respectively. Nine isolates were confirmed as hVISA by MET. Among 60 HA-MRSA isolates, ST239-MRSA-III was the most prevalent clone accounting for 51.7%, followed by ST5-MRSA-II clone. Fifty percentage and 22.2% of CA-MSSA isolates were found to be ST121 and ST88. ST239-MRSA-III was the predominant clone in hVISA isolates. However, no predominant ST type was found in HA-MSSA isolates. Of 9 PVL-positive strains, ST88 was the most prevalent ST (50.0%; 4/8), followed by ST121 (33.3%; 3/9), ST5 (4.5%; 1/22) and ST239 (2.6%; 1/39). In conclusion, ST239-III was the major pandemic clone in hVISA and HA-MRSA and spread in China. ST5-emerging rapidly in China had remained stable viability.

show abstract

Investigation of Reduced Susceptibility to Glycopeptides among Methicillin-Resistant Staphylococcus aureus Isolates from Patients in Ireland and Evaluation of Agar Screening Methods for Detection of Heterogeneously Glycopeptide-Intermediate S. aureus

Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) isolates (n ‫؍‬3

Cited by 36 publications

References 22 publications

The First Vancomycin-Intermediate Staphylococcus aureus Strains Isolated from Patients in Thailand

The First Vancomycin-Intermediate Staphylococcus aureus Strains Isolated from Patients in Thailand

Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

Molecular characteristic of Staphylococcus aureus isolates in a Chinese teaching hospital

Contact Info

Product

Resources

About